Geographic Atrophy

According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.

Researchers from the UKB Eye Clinic, in cooperation with the University of Bonn and in close collaboration with basic and clinical scientists, have examined patients with early forms of AMD. The researchers focused on the so-called iRORA lesions, which are very early anatomical signs of retinal damage.

Comanagement is a key component for treatment of disease.

Durga Borkar, MD, MMCi, recently discussed the quality data (Qdata, Verana Health) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data.

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

Repeated 0.1-ml intravireal injections of lampalizumab, antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D, seem to be associated with a low risk of elevated IOP

This PER On Air - Ophthalmology Times podcast examines the new treatment paradigm for patients with geographic atropy, following the introduction of complement-targeting therapies.

4D-175 will be evaluated in the GAZE clinical trial, an upcoming phase 1, open-label trial.

In this Ophthalmology Times EyePod podcast, Mandeep S. Singh, MD, PhD, speaks with Mark S. Humayun, MD, PhD, about the progress made by a team of USC researchers on a novel stem cell patch for treating advanced dry age-related macular degeneration.

The retrospective real-world evaluation of the drug considered several important as-yet-unanswered questions

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

The primary endpoint for the ReNEW and ReGAIN trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography (SD-OTC) and ellipsoid zone mapping at week 48.

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

An ophthalmologist presents the case of a 76-year-old woman who has geographic atrophy and progressively worsening vision in her right eye, with a history of macular macrovessel and choroidal hemangioma.

Katherine Talcott, MD, presents the case of a 64-year-old woman with geographic atrophy and a family history of age-related macular degeneration.

The hypothesis is based on a post hoc analysis of data from 2 phase 3 clinical trials of pegcetacoplan by Dun Jack Fu, PhD, and colleagues.

Data can clear a path to trends and strategies to meet patients’ needs

The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.

Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.

According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.

Researchers found the model demonstrated “near-perfect” detection capabilities.

According to the company, OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene.

Explore cutting-edge ophthalmology innovations in this new series on the Ophthalmology Times EyePod podcast. Throughout this series, we'll hear insights from various stakeholders in clinical practice, academia, and industry. In this episode, host Ehsan Sadri, MD, engages in a conversation with Jeffry Weinhuff, managing partner at Visionary Ventures, exploring trends and offering advice for individuals driven by an entrepreneurial mindset.